Maris Bard. Seven of these Mexican PVYNTN isolates, collected between 2013 and 2019, including two PVY isolates from potato tubers exhibiting potato tuber necrotic ringspot disease, were subjected to whole genome sequencing and found to show a typical PVYNTNa recombinant structure. When subjected to phylogenetic analysis, Mexican PVYNTN sequences clustered in more than three separate clades, suggesting multiple introductions of PVYNTN in the country. The wide circulation of the PVYNTN strain in Mexican potato should be taken into account by the potato producers, to develop mitigation strategies for this PVY strain associated with tuber necrotic symptoms.Rubbery rot of potato caused by Geotrichum candidum Link is characterized by symptoms of damp, flaccid tubers that feel rubbery when squeezed (Humpreys-Jones 1969), similar in consistency to potato diseases such as pink rot (caused by Phytophthora erythroseptica) and Pythium leak (caused by species of Pythium). In November 2019, several symptomatic tubers of potato variety 'Ciklamen' that had been held in storage since harvest and originated from an over-head irrigated, sandy-loam production field in Bingham county, Idaho were submitted to the University of Idaho for diagnosis. Shipping-point inspection records indicated 4-9% of tubers were affected. External symptoms included irregularly shaped, randomly located sunken black-colored lesions on more severely affected rubbery-textured tubers. When cut, internal affected tissue developed a greyish appearance after several minutes. Lens-shaped cavities were apparent in two of the tubers, indicating an advanced infection. A sour-milk smell accompanied the sample.tes (US) (Pritchard and Porte, 1923; Bourret et al., 2013), and potatoes with rubbery rot originating from Australia were intercepted at a US port (Farr et al., 2020), the disease has not to our knowledge been documented on potato grown in the US. Because symptoms may be confused with pink rot and Pythium leak, it is critical for producers to obtain a correct diagnosis to facilitate appropriate management strategies.
  In this study, we explored if professionals working with autistic people in different regions of the world perceive differences between females and males diagnosed with the condition. A total of 131 professionals responded to a survey that included an open question about gender differences in autism. Of these, 32 responded that they do not perceive gender differences in autism. The information provided by the other 99 experts was analyzed to identify common patterns. Three main differences were found, (1) 
  where professionals described differences in core symptoms of autism, and that autistic females were less similar to the conceptualization of autism. In (2) 
  , professionals described that autistic males display more apparent problems including hyperactivity, while autistic females were perceived as having more internalizing issues such as anxiety and eating disorders. In the last category, (3) 
  , experts perceived autistic females as more socially motivated, and more inclined to camouflage social difionals working in different parts of the world acknowledge gender differences in autism, but also that there might be some regional differences. Finally, we found that gender differences reported by the international professionals could largely be assessed with a shortened version of the International Classification of Functioning by the World Health Organization, specifically developed for autism.
  The PRECEDE-PROCEED model (PPM) is a community-based participatory research (CBPR) framework for health promotion, yet the direct application of the PPM into practice is unclear. This paper describes how the PPM was adapted for the development and application of a pilot intervention study to promote outdoor physical activity (PA) in older adults (OUTDOOR ACTIVE). We illustrate the steps and adaptations we applied to put the PPM into practice and present the developed interventions.
 
  The PPM was adapted by incorporating a socio-ecological model. This ensured the design of any resultant intervention would explicitly address multi-level determinants of physical activity. The list of possible program components to select from for the design of an intervention was also extended.
 
  Bremen, Germany.
 
  Participants in the intervention development were 924 noninstitutionalized older adults, aged 65-75 years (response 25.2%), living in Bremen-Hemelingen, Germany. For implementation of the intervention and to ensure PM is a promising starting point for developing multi-level interventions. Steps should be taken to ensure all social groups are participating in the process and all levels of determinants are addressed.
  There is limited real-world evidence on using ixekizumab in psoriasis patients. Therefore, we characterized patients with psoriasis initiating ixekizumab and report 6-month changes in disease and patient-reported outcomes.
 
  Adult patients with psoriasis who initiated ixekizumab and completed a 6-month follow-up visit were enrolled from the Corrona Psoriasis Registry. Disease characteristics and outcomes were assessed at ixekizumab initiation.  https://www.selleckchem.com/products/rbn-2397.html  Outcomes included the mean 6-month change in Psoriasis Area and Severity Index (PASI), body surface area (BSA), Investigator Global Assessment (IGA), and IGA*BSA.
 
  From baseline to follow-up in all patients (
   = 136), means decreased for IGA*BSA (-45.5) and BSA (-12.4), and a higher % achieved an absolute PASI ≤ 5 (84.6%), BSA 0-3 (72.1%), and IGA 0/1 (50.7%). Within stratified groups, means decreased for PASI <12 for IGA*BSA (-21.1) and BSA (-6.3); PASI≥12 for IGA*BSA (-94.8) and BSA (-24.6); weight <100 kg for IGA*BSA (-45.1) and BSA (-12.4); weight ≥100 kg for IGA*BSA (-46.2) and BSA (-12.3); concomitant PsA for IGA*BSA (-56.0) and BSA (-15.3); and in no concomitant PsA for IGA*BSA (-36.9) and BSA (-10.0).
 
  We provide real-world evidence on the benefits of ixekizumab for treating psoriasis, regardless of baseline disease severity, weight, or concomitant PsA.
 We provide real-world evidence on the benefits of ixekizumab for treating psoriasis, regardless of baseline disease severity, weight, or concomitant PsA.